生物膜是病原微生物耐药的主要原因，从具有抗生物膜活性的天然产物中筛选新型抗生素，具有重要意义。单纯疱疹病毒1型（HSV-1）感染具有噬神经性，极易形成潜伏感染，治愈性较差且易复发，研究开发针对不同作用靶点、安全有效的抗HSV-1新药迫在眉睫。深海微生物被认为是众多尚未被发掘和利用的新颖生物活性物质的重要生产源，是人类寻找和开发新型天然药物的宝库。在前期，申请人研究团队已构建一个深海特境真菌资源库，从中发现个别新型抗生物膜形成和抗HSV-1（统称抗感染）活性化合物。本项目拟在此基础上，继续从冲绳海槽热液口和东印度洋深海来源真菌中发掘新型抗感染活性化合物，探究个别结构新颖、活性显著的抗感染化合物的作用机制，为研制原创性有知识产权的新型抗生素和抗病毒新药提供候选先导化合物。

Biofilm is a major cause of pathogenic microorganism resistance. It is very important to screen new antibiotics from natural products with anti-biofilm activity. Herpes simplex virus type 1 (HSV-1) infection has neuronophagia, easily forming a latent infection, which makes its cure poor and produces recurrent. It is urgent to develop safe and effective anti-HSV-1 new drugs with different drug targets. Deep-sea microbe is considered to be an important source for discovering novel bioactive substances, and the last frontier for searching and developing new natural medicines. The research team have built a repository that contains many deep-sea-derived fungal strains, and found several new anti-biofilm and anti-HSV-1 compounds. On this basis, the project aims to continue to find new anti-biofilm and anti-HSV-1 compounds from deep-sea-derived fungi isolated from sediments of the Okinawa trough hydrothermal and East Indian Ocean, and study the mechanisms of action of novel bioactive compounds. This study will provide new anti-biofilm and anti-HSV-1 candidates with intellectual property for the development of new antibiotic and antiviral drugs.